SARS-CoV-2 neutralizing antibodies for COVID-19: Outcomes for bamlanivimab versus bamlanivimab-etesevimab combination in a racially diverse cohort of patients with significant comorbiditiesArticle Published on 2022-09-012022-11-15 Journal: Journal of clinical pharmacy and therapeutics [Category] COVID19(2023년), SARS, 진단, [키워드] 30-Day mortality BAM bamlanivimab black changed clinical trials Cohort cohort of patient Combination Comorbidity comparable coronavirus disease COVID-19 etesevimab etesevimab. evaluated groups high-risk patient Hospitalization incidence laboratory-confirmed LOS male median age Median BMI monoclonal antibody monotherapy Neutralizing outcome outcomes Outpatient Patient provided receiving recent reduced Result retrospective cohort study SARS-CoV-2 SARS-CoV-2 neutralizing antibody secondary shown significantly symptom onset treated [DOI] 10.1111/jcpt.13694 PMC 바로가기
SARS-CoV-2 Vaccine Response in Patients With Autoimmune HepatitisArticle Published on 2022-09-012022-11-15 Journal: Clinical gastroenterology and hepatology : the off [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] acute respiratory syndrome Autoimmune hepatitis China chronic liver disease Cohort coronavirus coronavirus disease death decrease disorder Europe glucocorticoid Hospitalization Immune-mediated Immunocompromised patients immunogenic inactivated incidence increased risk Inflammatory bowel disease Liver disease morbidity and mortality multicenter Patient provide reduce reduced response SARS-CoV-2 Serologic response shown the healthy vaccination vaccine-induced antibody variants of concern whole-virion SARS-CoV-2 vaccine [DOI] 10.1016/j.cgh.2022.04.006 PMC 바로가기
Two-Year Health Outcomes in Hospitalized COVID-19 Survivors in ChinaArticle Published on 2022-09-012022-11-16 Journal: JAMA Network Open [Category] SARS, 변종, [키워드] 95% CI acute illness Admission age Analysis Anxiety change Chest China chronic obstructive cohort study conducted COVID-19 decrease defined discharge Dyspnea Factor fatigue Follow-up follow-up study follow-up visits Health higher risk hospital hospital discharge Hospitalization hospitalized COVID-19 identify incidence increased risk Infection intensive care IQR longitudinal cohort study male median MOST myalgia Odds ratio omicron outcome Patient patients who survived patients with COVID-19 persistence pulmonary disease questionnaire required resolved severe disease Severity of disease survivor Survivors Symptom symptom burden Symptoms total score variant virus World Health Organization worsening Wuhan, China [DOI] 10.1001/jamanetworkopen.2022.31790 PMC 바로가기
Obesity, Hypovitaminosis D, and COVID-19: the Bermuda Triangle in Public Health비만, 비타민 D 부족 및 COVID-19: 공중 보건의 버뮤다 삼각지대Review Published on 2022-09-012022-09-11 Journal: Current obesity reports [Category] COVID19(2023년), SARS, 유전자 메커니즘, [키워드] acute respiratory distress acute respiratory distress syndrome association body mass body mass index convergence COVID-19 COVID-19 pandemic COVID-19 susceptibility death Evidence explain Genetic genetic data genetic evidence Genome-wide association studies Genome-wide association study higher risk highlighting Hospitalization hypovitaminosis Hypovitaminosis D independent risk factor Infectious complications measure morbidity and mortality obesity outcomes pandemic Pandemics potential mechanism potential mechanisms Prevalence prevalent Public public health recent required respiratory distress risk risk factor robust SARS-CoV-2 SARS-COV-2 infection severe disease severity Severity of disease shown subject suggested syndrome therapeutic Treatment treatment of COVID-19 Triangle Vitamin D vitamin D level vitamin D levels Vitamin D supplementation [DOI] 10.1007/s13679-022-00471-3 PMC 바로가기 [Article Type] Review
Durable functional limitation in patients with coronavirus disease-2019 admitted to intensive care and the effect of intermediate-dose vs standard-dose anticoagulation on functional outcomesRandomized Controlled Trial Published on 2022-09-012022-10-05 Journal: European journal of internal medicine [Category] COVID19(2023년), SARS, 임상, [키워드] affected airway anticoagulation clinical trial coronavirus coronavirus disease COVID-19 depressive symptom Depressive symptoms disease Exercise limitation Follow-up form functional Health Hospitalization ICU ICU patient impair IMPROVE intensive care intermediate limitation mental health multiple organ failure Odds ratio outcome outcomes participated Patient Patient health questionnaire-2 patients died patients with COVID-19 PHQ-2 Prophylactic prophylactic anticoagulation proportion Randomized Randomized controlled trial randomized patient Standard-dose Survivors The post-COVID-19 functional status scale. trial participants with COVID-19 women [DOI] 10.1016/j.ejim.2022.06.014 PMC 바로가기 [Article Type] Randomized Controlled Trial
Patient-centered outcomes at hospital discharge in mechanically ventilated COVID-19 patients in Kobe, Japan: A single-center retrospective cohort studyResearch article Published on 2022-09-012022-10-05 Journal: Respiratory investigation [Category] 변종, [키워드] Activities of Daily Living adult COVID-19 patient clinical clinically Comorbidity conducted coronavirus disease COVID-19 COVID-19 infection COVID-19 patient Critical care demonstrated died discharge Dyspnea functional hospital discharge Hospitalization ICU in-hospital mortality independent intensive care interquartile range invasive Japan Kobe mechanical ventilation mechanically ventilated median age on mechanical ventilation organ dysfunction organ function outcome Patient receiving required Respiratory Support respiratory symptoms Result retrospective cohort study Retrospective study single-center survived survivor Survivors the patient was related [DOI] 10.1016/j.resinv.2022.06.010 [Article Type] Research article
First-generation oral antivirals against SARS-CoV-2Review article Published on 2022-09-012022-10-05 Journal: Clinical microbiology and infection : the official [Category] COVID19(2023년), SARS, 치료제, [키워드] acute respiratory syndrome Antiviral antiviral agent Clinical practice clinical trials Compliance content coronavirus COVID-19 death drug drug-drug interaction early administration Efficacy Emergency use authorization Frequency Google Scholar high risk Hospitalization Hospitalized Immunosuppressed include individual ingestion Mild-to-moderate molnupiravir Nirmatrelvir objective oral Patient persistence progression reduced reference Regulatory required risk reduction Ritonavir SARS-CoV-2 Source Toxicity Treatment website [DOI] 10.1016/j.cmi.2022.04.015 [Article Type] Review article
Curbing the Delta Surge: Clinical Outcomes After Treatment With Bamlanivimab-Etesevimab, Casirivimab-Imdevimab, or Sotrovimab for Mild to Moderate Coronavirus Disease 2019Article Published on 2022-09-012022-11-15 Journal: Mayo Clinic proceedings [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] Admission B.1.617.2 Care clinical Clinical outcome Cohort comparable coronavirus disease COVID-19 COVID-19 vaccination death Delta high-risk patient Hospitalization intensive care large cohort Mild moderate Moderate COVID-19 Mortality outcome oxygen supplementation Patient patients treated Rate Respiratory Coronavirus Retrospective study SARS-CoV-2 severe disease significantly lower Sotrovimab the SARS-CoV-2 Treatment were assessed [DOI] 10.1016/j.mayocp.2022.06.015 PMC 바로가기
Decreased Passive Immunity to Respiratory Viruses through Human Milk during the COVID-19 PandemicArticle Published on 2022-08-312022-11-15 Journal: Microbiology Spectrum [Category] 진단, [키워드] antibodies antibody association binding breast milk circulation consequence Coronaviruses COVID-19 COVID-19 pandemic decrease Decreased develop explain HCoV-HKU1 HCoV-NL63 HCoV-OC43 help Hospital admission Hospitalization Human human milk Humoral immunity hygiene IgA IgG IgG level immune system Immunity Infant Infants Infection infections Influenza lifted lockdown Luminex assay measure milk mother pandemic Passive passive immunity predict Prevent preventative measure preventative measures provide reduced respiratory respiratory infections respiratory syncytial virus respiratory virus resulting RSV seasonal coronavirus serum subsequent viral respiratory virus viruses was reduced [DOI] 10.1128/spectrum.00405-22 PMC 바로가기
Genomic epidemiology and emergence of SARS-CoV-2 variants of concern in the United Arab Emirates Research Published on 2022-08-292022-10-05 Journal: Scientific Reports [Category] SARS, 변종, 유전자 메커니즘, 진단, 치료기술, [키워드] A.23.1 adopted Analysis B.1 B.1.1 B.1.1.7 B.1.351 clade collected contribute demonstrated epidemiological Epidemiology Frequency highest Hospitalization Hospitalized International Local measure Measures Mutation occur ORF1a outbreak pandemic positive proportion provide public health authority reduce RT-PCR SARS-CoV-2 SARS-CoV-2 variant sequenced Seven significantly Spread Surveillance Transmission transmission of SARS-CoV-2 United Arab Emirate variants variants of concern variants of interest viral sequence VoC VOCs VOI VOIs [DOI] 10.1038/s41598-022-16967-w [Article Type] Research